Contact Us

Mr. Kazmierczak is a venture developer practiced in the execution of growth strategy for companies ranging from Fortune 100 to seed-stage competing globally across a spectrum of industries. His 25-year track record of producing outstanding stakeholder wealth reflects his passion for building breakthrough businesses and the premium value he places on transparency, integrity, and results. Walter holds an MBA in International Finance from Suffolk University and BA in Economics from Yale.  

Ms. Welz is expert in intellectual property and tax law and serves as KMG's General Counsel. Her career spans 30 years as Senior Counsel in Corporate Tax at John Hancock Financial Services, Inc., Tax Law Associate at Rackemann, Sawyer & Brewster, and Tax Specialist at Coopers & Lybrand. Ella earned her J.D. at Northeastern University’s School of Law, Masters of Laws in Taxation (L.L.M.) at Boston University School of Law, and Bachelor of Arts at Harvard. 

Michael is a Partner at Haynes and Boone, LLP. He is a leading U.S. litigator specializing in Environmental Law representing Fortune 100 energy and industrial clients. He is licensed to practice in Louisiana, Texas, and Massachusetts, all Federal courts in Texas, the United States Court of Appeals for the Fifth Circuit, the United States Supreme Court, is Board Certified in Civil Trial Law, and is a member of the American Arbitration Association’s National Panel of Arbitrators. Michael received his undergraduate degree in Business Administration from the University of South Carolina, attended graduate school at the University of Michigan, and earned his J.D. from Suffolk University Law School.

Dr. Ronsheim is Chief Operating Officer at Xenon Pharmaceuticals Inc. Matt has 25 years of experience bringing important medicines from discovery through clinical development, global regulatory filings and approvals, and commercial launch and supply. Before joining Xenon, Matt was President of Innoviva Specialty Therapeutics, having previously served as their Chief Technical Officer. Prior to this, he was President of Entasis Therapeutics, which was acquired by Innoviva, Inc. in 2022. Throughout his career, Matt has held leadership roles overseeing research, CMC, pharmaceutical development, and commercialization at companies including Merck/Cubist Pharmaceuticals, Enanta Pharmaceuticals, and Forest Laboratories. Matt's contributions and leadership have contributed to delivering important therapies across several disease areas including central nervous system disorders.  His broad end-to-end experience includes development and commercialization of novel therapeutics, Bio Tech M&A, regulatory filings in the US, EU and Latin American countries, and patents. Matt holds a B.S. in Chemistry from Southern Connecticut State University and a Ph.D. in Synthetic Organic Chemistry from the University of New Hampshire. 

Marcin is a biotech entrepreneur and founder of AmebaGone, Inc., Agrafilms, Inc. and Conjugon/Atterx Biotherapeutics, Inc. He serves as President & Chief Science Officer at Amebagone and Agrafilms. Accomplished in developing and commercializing innovative approaches to combat infectious agents by harnessing the natural antibiotic properties of non-pathogenic microbes, Marcin holds a Doctoral Degree in Molecular Biology from the Polish Academy of Science, conducted post-doctoral research on microbial genetics at the University of California in San Diego, and was Professor of Bacteriology at University of Wisconsin, Madison.

Gene is Chief Financial Officer of global asset management firm Alpha Innovations Ltd. An economist expert in international business and M&A, early in his career Gene was one of a two-person team that created the first global offshore hedge fund at Furman Selz which invested in equity and debt products worldwide across 10+ currencies and was one of the first businessmen to penetrate Mainland China through US equity partnerships. His 20-year career spans both buy and sell sides, fund development, and equity research at top-tier Wall Street firms including Paine Weber and ING Barings, and as co-founder of FS Capital. Gene holds a BS in Business Economics from the State University of New York, MBA in International Business from Adelphi University, and Masters of Engineering from MIT.